Gene · 7832
Papers2,269
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
81 to 100 of 2,269
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Beyond Blacklists: A Critical Assessment of Exclusion Set Generation Strategies and Alternative Approaches. | bioRxiv | 2025 | 39975128 | PubTator, text mining | PubMed |
| LncRNA PVT1 links estrogen receptor alpha and the polycomb repressive complex 2 in suppression of pro-apoptotic genes in hormone-responsive breast cancer. | Cell Death Dis | 2025 | 39922814 | PubTator, text mining | PubMed |
| High-Dose Methotrexate, Ibrutinib, and Temozolomide in the Treatment of Newly Diagnosed Primary CNS Lymphoma: A Multicenter, Prospective Phase II Study. | Blood Cancer Discov | 2025 | 39913173 | PubTator, text mining | PubMed |
| B cell translocation gene 2 expression levels in human granulosa cells is negatively associated with in vitro fertilization/intracytoplasmic sperm injection outcomes: a pilot study. | J Assist Reprod Genet | 2025 | 39856376 | PubTator, text mining | PubMed |
| Impact of 17-alpha ethinyl estradiol (EE2) and diethyl phthalate (DEP) exposure on microRNAs expression and their target genes in differentiated SH-SY5Y cells. | Sci Rep | 2025 | 39837947 | PubTator, text mining | PubMed |
| Single cell transcriptomics in blood of patients with chronic obstructive pulmonary disease. | BMC Pulm Med | 2025 | 39810158 | PubTator, text mining | PubMed |
| The regulatory role of KIAA1429 in epithelial-mesenchymal transition in cervical cancer via mediating m6A modification of BTG2. | Cytotechnology | 2025 | 39760059 | PubTator, text mining | PubMed |
| LncRNA MIR600HG inhibits laryngeal cancer development by mediating the miR-424-5p/BTG2 axis. | Cancer Sci | 2025 | 39618050 | PubTator, text mining | PubMed |
| The tumor suppressor SALL2 opposes chemotherapeutic resistance in breast cancer. | Mol Cell Biochem | 2025 | 39572504 | PubTator, text mining | PubMed |
| LncRNA ZFAS1/miR-186-5p axis is involved in oxidative stress inhibition of myocardial ischemia-reperfusion injury by targeting BTG2. | Expert Rev Clin Immunol | 2025 | 39365123 | PubTator, text mining | PubMed |
| Predictive models of sarcopenia based on inflammation and pyroptosis-related genes. | Front Genet | 2024 | 39777262 | PubTator, text mining | PubMed |
| Identification and validation of the diagnostic biomarker MFAP5 for CAVD with type 2 diabetes by bioinformatics analysis. | Front Immunol | 2024 | 39749331 | PubTator, text mining | PubMed |
| Developing the new diagnostic model by integrating bioinformatics and machine learning for osteoarthritis. | J Orthop Surg Res | 2024 | 39695788 | PubTator, text mining | PubMed |
| The roles of LncRNA CARMN in cancers: biomarker potential, therapeutic targeting, and immune response. | Discov Oncol | 2024 | 39692999 | PubTator, text mining | PubMed |
| Role of fatty acid metabolism-related genes in periodontitis based on machine learning and bioinformatics analysis. | Hua Xi Kou Qiang Yi Xue Za Zhi | 2024 | 39610070 | PubTator, text mining | PubMed |
| Combining single-cell RNA sequencing and network pharmacology to explore the target of cangfu daotan decoction in the treatment of obese polycystic ovary syndrome from an immune perspective. | Front Pharmacol | 2024 | 39539629 | PubTator, text mining | PubMed |
| Putative mechanisms of primary resistance to EGFR-targeted therapies: A retrospective study. | Lung Cancer | 2024 | 39490204 | PubTator, text mining | PubMed |
| [Analysis of Therapeutic Efficacy and Adverse Prognostic Factors of Secondary Central Nervous System Lymphoma]. | Zhongguo Shi Yan Xue Ye Xue Za Zhi | 2024 | 39479826 | PubTator, text mining | PubMed |
| [Efficacy and safety analysis of the OR-CHOP regimen for the treatment of MCD subtype diffuse large B cell lymphoma in the real-world setting]. | Zhonghua Xue Ye Xue Za Zhi | 2024 | 39414605 | PubTator, text mining | PubMed |
| The DHODH inhibitor teriflunomide impedes cell proliferation and enhances chemosensitivity to daunorubicin (DNR) in T-cell acute lymphoblastic leukemia. | Ann Hematol | 2024 | 39377943 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7832/papers?page=5